DE69631376T2 - Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie - Google Patents

Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie Download PDF

Info

Publication number
DE69631376T2
DE69631376T2 DE69631376T DE69631376T DE69631376T2 DE 69631376 T2 DE69631376 T2 DE 69631376T2 DE 69631376 T DE69631376 T DE 69631376T DE 69631376 T DE69631376 T DE 69631376T DE 69631376 T2 DE69631376 T2 DE 69631376T2
Authority
DE
Germany
Prior art keywords
branched
straight
alkyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631376T
Other languages
German (de)
English (en)
Other versions
DE69631376D1 (de
Inventor
J. William CHRIST
P. Daniel ROSSIGNOL
Seiichi Kobayashi
Tsutomu Kawata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23833509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69631376(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE69631376D1 publication Critical patent/DE69631376D1/de
Application granted granted Critical
Publication of DE69631376T2 publication Critical patent/DE69631376T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DE69631376T 1995-06-05 1996-06-05 Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie Expired - Lifetime DE69631376T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US461675 1983-01-27
US08/461,675 US5750664A (en) 1995-06-05 1995-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
PCT/US1996/009578 WO1996039411A1 (en) 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Publications (2)

Publication Number Publication Date
DE69631376D1 DE69631376D1 (de) 2004-02-26
DE69631376T2 true DE69631376T2 (de) 2004-11-11

Family

ID=23833509

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631376T Expired - Lifetime DE69631376T2 (de) 1995-06-05 1996-06-05 Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie

Country Status (21)

Country Link
US (8) US5750664A (enExample)
EP (1) EP0853627B1 (enExample)
JP (3) JP4009318B2 (enExample)
KR (1) KR100416335B1 (enExample)
CN (1) CN1067082C (enExample)
AT (1) ATE258185T1 (enExample)
AU (1) AU707779C (enExample)
CA (1) CA2223140C (enExample)
DE (1) DE69631376T2 (enExample)
DK (1) DK0853627T3 (enExample)
ES (1) ES2214543T3 (enExample)
HU (1) HU221342B1 (enExample)
IL (2) IL122251A0 (enExample)
MX (1) MX9709502A (enExample)
NO (1) NO310239B1 (enExample)
NZ (1) NZ312299A (enExample)
PT (1) PT853627E (enExample)
RU (1) RU2170738C2 (enExample)
TW (1) TW366345B (enExample)
WO (1) WO1996039411A1 (enExample)
ZA (1) ZA964666B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
CN1150001C (zh) * 1996-07-03 2004-05-19 卫材株式会社 含有脂质a类似物的注射剂及其制备方法
US6828155B1 (en) 1998-09-01 2004-12-07 Eisai Co., Ltd. Method for evaluating lipid a analog-containing injections
EP2298326A3 (en) * 1999-01-14 2011-04-27 Eisai R&D Management Co., Ltd. Administration of an anti-endotoxin drug by intravenous infusion
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
TW527358B (en) * 1999-02-10 2003-04-11 Sankyo Co Ether type lipid A1 position carboxylic acid analogue
JP2003524638A (ja) * 2000-01-14 2003-08-19 エーザイ株式会社 手術に伴う内毒素血症及び関連する合併症の予防及び治療
US20050101549A1 (en) * 2000-01-14 2005-05-12 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
AU2001238507C9 (en) * 2000-02-18 2005-07-07 Eisai R&D Management Co., Ltd. Micelles
US6861512B2 (en) * 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
WO2001093921A2 (en) * 2000-06-09 2001-12-13 Eisai Co., Ltd. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
WO2002088062A1 (en) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Process for preparation of alcohol derivatives
JPWO2002088072A1 (ja) * 2001-04-23 2004-08-12 エーザイ株式会社 アルキレン化合物の製造方法
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
WO2002094019A1 (en) * 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
DE10125179A1 (de) * 2001-05-23 2002-12-05 Laves Ralph Georg Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse
WO2003013440A2 (en) 2001-08-10 2003-02-20 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003050137A2 (en) * 2001-12-11 2003-06-19 David Schwartz Toll-like receptor 4 mutations
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
WO2004058788A1 (ja) * 2002-12-24 2004-07-15 Sankyo Company, Limited 右糖グルコースリピドa類縁体
MXPA05007295A (es) * 2003-01-06 2005-09-30 Corixa Corp Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso.
DE602004021901D1 (de) * 2003-01-28 2009-08-20 Academisch Ziekenhuis Leiden Aus ll-37 abgeleiteten peptidinhibitoren von toxinen
JP4773336B2 (ja) * 2003-02-20 2011-09-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｐｓアンタゴニストｂ１２８７およびその立体異性体の調製のための試薬および方法
BRPI0408077A (pt) * 2003-03-05 2006-02-14 Eisai Co Ltd composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições
WO2005027826A2 (en) * 2003-07-14 2005-03-31 Eisai, Co, Ltd. Methods and treating severe acute respiratory syndrome
WO2005059517A2 (en) 2003-12-16 2005-06-30 University Of Massachusetts Toll-like receptor assays
EP1702926A4 (en) * 2004-01-08 2010-03-17 Sankyo Co LEVULOSEGLUCOSELIPID-A-ANALOG
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
JP5185813B2 (ja) 2005-04-26 2013-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌免疫治療のための組成物および方法
WO2006138681A2 (en) * 2005-06-17 2006-12-28 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
JP5118968B2 (ja) * 2005-08-31 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体の製造方法
WO2007026675A1 (ja) * 2005-08-31 2007-03-08 Eisai R & D Management Co., Ltd. リピッドａ類縁体の製造方法
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
KR101541551B1 (ko) 2006-11-22 2015-08-03 에자이 알앤드디 매니지먼트 가부시키가이샤 이당류 화합물의 나트륨염 및 그의 제조 방법 및 그의 사용
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
AU2007323134B2 (en) 2006-11-23 2013-05-02 Cadila Pharmaceuticals Limited Poly-TLR antagonist
WO2011035026A1 (en) * 2009-09-16 2011-03-24 Heidi Ehrentraut Methods for treating myocardial disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
JP2012246470A (ja) 2011-05-31 2012-12-13 Sharp Corp 半導体ナノ粒子の製造方法、半導体ナノ粒子、ならびにこれを用いた蛍光体
EP2794464B1 (en) * 2011-12-22 2023-11-22 Samsung Electronics Co., Ltd. Surface modified nanoparticles
KR20140139063A (ko) 2012-03-28 2014-12-04 유니버시티 오브 매릴랜드, 발티모어 오르토믹소바이러스 감염 치료를 위한 에리토란 또는 그의 제약학상 허용가능한 염의 투여
WO2014113048A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
EP3019200B1 (en) 2013-07-11 2022-03-23 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9584991B1 (en) * 2014-06-19 2017-02-28 Isaac S. Daniel Method of communicating and accessing social networks using interactive coded messages
CA3015494C (en) * 2016-03-30 2021-10-26 Ayuvis Research, Inc. Novel compositions and therapeutic methods
US10570074B2 (en) * 2016-09-14 2020-02-25 Genomatica, Inc. 1,3-fatty diol compounds and derivatives thereof
JP7069120B2 (ja) 2016-09-16 2022-05-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 エボラ（ｅｂｏｌａ）及びマールブルク（ｍａｒｂｕｒｇ）病を治療するためのｔｌｒ４拮抗薬としてのエリトランの使用方法
CN112930184B (zh) * 2018-12-17 2024-07-12 卫材R&D管理有限公司 包含脂质体的配制品
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
HU199494B (en) * 1985-06-28 1990-02-28 Sandoz Ag Process for producing new saccharides and pharmaceutical compositions comprising same
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JP2839916B2 (ja) * 1989-10-20 1998-12-24 三共株式会社 リピドａ３位エーテル類縁体
DD295854A5 (de) 1989-12-11 1991-11-14 ��@���������@�������k�� Lipid-a-austauschstoffe mit immunoaktivierender und antitumorwirkung
JP2847319B2 (ja) 1990-05-18 1999-01-20 イビデン株式会社 電子部品搭載用多層ボンディング基板
JP3040847B2 (ja) 1990-06-22 2000-05-15 三共株式会社 リピドｘ類縁体
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
JP3135990B2 (ja) 1992-07-31 2001-02-19 沖電気工業株式会社 パリティ付加回路
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
JP3967769B2 (ja) * 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
US5750664A (en) 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
JP4235193B2 (ja) 2005-06-07 2009-03-11 日本電信電話株式会社 イベント履歴蓄積装置、イベント情報検証装置、イベント履歴蓄積方法、イベント情報検証方法およびイベント情報処理システム

Also Published As

Publication number Publication date
CA2223140C (en) 2008-08-05
AU707779B2 (en) 1999-07-22
KR100416335B1 (ko) 2004-07-27
DE69631376D1 (de) 2004-02-26
NZ312299A (en) 1999-08-30
CN1067082C (zh) 2001-06-13
ES2214543T3 (es) 2004-09-16
NO975644L (no) 1998-02-04
RU2170738C2 (ru) 2001-07-20
ATE258185T1 (de) 2004-02-15
US7737129B2 (en) 2010-06-15
US7994154B2 (en) 2011-08-09
WO1996039411A1 (en) 1996-12-12
MX9709502A (es) 1998-10-31
DK0853627T3 (da) 2004-06-01
JP2011121970A (ja) 2011-06-23
AU707779C (en) 2001-12-06
US5935938A (en) 1999-08-10
US6184366B1 (en) 2001-02-06
KR19990022104A (ko) 1999-03-25
EP0853627A1 (en) 1998-07-22
CN1192216A (zh) 1998-09-02
JPH11506793A (ja) 1999-06-15
IL122251A0 (en) 1998-04-05
US5750664A (en) 1998-05-12
NO310239B1 (no) 2001-06-11
AU6380296A (en) 1996-12-24
US20020028927A1 (en) 2002-03-07
IL149971A (en) 2010-04-29
EP0853627A4 (en) 1998-10-07
US20080214802A1 (en) 2008-09-04
US20100227835A1 (en) 2010-09-09
NO975644D0 (no) 1997-12-04
JP2007269812A (ja) 2007-10-18
JP4009318B2 (ja) 2007-11-14
EP0853627B1 (en) 2004-01-21
HUP9802662A2 (hu) 1999-05-28
HUP9802662A3 (en) 1999-06-28
TW366345B (en) 1999-08-11
PT853627E (pt) 2004-05-31
HU221342B1 (en) 2002-09-28
JP4712001B2 (ja) 2011-06-29
US20030144503A1 (en) 2003-07-31
CA2223140A1 (en) 1996-12-12
US5681824A (en) 1997-10-28
ZA964666B (en) 1997-03-11

Similar Documents

Publication Publication Date Title
DE69631376T2 (de) Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie
DE60017801T2 (de) Inhalierung von anti-endotoxinmitteln zur vorbeugung oder behandlung von bakterieller lungeninfektion oder symptomatischer endotoxinaussetzung der lunge
EP1964844B1 (de) Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE60009665T2 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
DE60215530T2 (de) Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält
EP0845475B1 (de) Inositolglykane mit insulinartiger Wirkung
DE3876174T2 (de) 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirus-infektionen.
EP0312086A2 (de) Polyschwefelsäureester von Bis-aldonsäureamiden und deren Derivaten, Verfahren zu ihrer Herstellung und Arzneimittel
DE60032470T2 (de) Heilmittel die sulfopyranosylacylglycerolderivate enthalten
DE69818823T2 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE60016908T2 (de) Verwendung von Sulfoquinovosylglycerol-Derivativen als Immunosuppressiva
DE69427966T2 (de) Neue o-sulfatierte ganglioside und lyso-ganglioside-derivaten
DE60008300T2 (de) Oligosaccharide, Verfahren zur ihrer Herstellung und pharmazeutische Zusammensetzung die sie enthalten
DE2307795C3 (de) 11 beta 17alpha, 21 Trihydroxy-6
HK1051490B (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKIO, JP